Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Closure Medical (CLSR) fomerly Tri-Point Medical (TPMC) -- Ignore unavailable to you. Want to Upgrade?

To: David S. who wrote (124)	3/21/1998 5:28:00 PM
From: RevMikeB	Read Replies (2) \| Respond to of 184

David, do you have any ideas why CLSR is having so many problems selling their product in England? Is there lack of interest? Problems with the product? Problems with shipping? Problems with sales force? Or are they just getting started there and there hasn't been enough time yet to really judge. There are lots of unanswered questions, which makes people doubt how marketable Dermabond will be in U.S. after approval. But given all the suggested benefits (faster application than stitches, no shots to numb tissue like for stitches, no need for second doctor's visit to remove stitches, hardly noticeable increase in infections, less scarring)I got to think the rumors aren't much to worry about. What do you think the new factory will do to next quarter's earnings? I don't think the numbers are going to look to good, but I have to believe the move to the new building was necessary step to prepare for major production for U.S. market. That day the announcement was made, stock took a tumble. When do they expect to get final FDA approval in U.S. anyway?